



**Press release**  
October 27, 2016  
Gothenburg

## Clarification of news about two LS™ contract signed in Spain

XVIVO Perfusion (the Company) announced earlier today at the Company's website the news that two LS™ contracts was concluded in Spain, which were the first two LS™ contracts XVIVO Perfusion signed and the first lung evaluation machines (EVLP machines named LS™ and XPS™) to Spain.

XVIVO Perfusion clarifies that according to the Company's business model, the pricing strategy for capital goods, which are EVLP machines named LS™ and XPS™, is designed to allow the sale of capital goods to not have a significant financial impact on the company. According to the company's pricing strategy the future sales using the EVLP machines through sales of STEEN Solution™ and related disposables is of financial importance for the Company.

As the number of clinics that perform lung transplants in Europe are only around 80, the deployment of EVLP machines is of significant importance because the sale of EVLP machines is a prerequisite for the company to monetize the use of these machines. In addition, these EVLP machines are the first to Spain, which carries a high proportion (13 percent in 2014 according GODT) of the total number of lung transplants in Europe.

October 27, 2016  
Gothenburg  
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, tel: +1 720 616 2101, email: [christoffer.rosenblad@xvivoperfusion.com](mailto:christoffer.rosenblad@xvivoperfusion.com)

Magnus Nilsson, CEO, tel +46 31 788 2150, email: [magnus.nilsson@xvivoperfusion.com](mailto:magnus.nilsson@xvivoperfusion.com)

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on Nasdaq First North Premier and has the ticker symbol XVIVO. More information can be found on the website [www.xvivoperfusion.com](http://www.xvivoperfusion.com). The Certified Adviser is Redeye, [www.redeye.se](http://www.redeye.se).

---

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.  
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.  
E-mail: [info@xvivoperfusion.com](mailto:info@xvivoperfusion.com). Website: [www.xvivoperfusion.com](http://www.xvivoperfusion.com)

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 5:15 p.m. CET on October 27, 2016.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.